Royal Philips has introduced the EPIQ CVx cardiovascular ultrasound system.
Royal Philips has introduced the EPIQ CVx cardiovascular ultrasound system. Built on the powerful EPIQ ultrasound platform, EPIQ CVx is specifically designed to increase diagnostic confidence and simplify workflow for clinicians, giving them more time to interact with their patients and reducing the need for repeat scans. The initial response to the new system has been overwhelmingly positive: 95% of a group of clinicians who were shown the new EPIQ CVx believed it offered improved image quality: sharper and clearer images Philips is also introducing the EPIQ CVxi, specifically tailored for use in the interventional lab. EPIQ CVx and EPIQ CVxi are CE marked and have received 510(k) clearance from the FDA.
Designed for cardiology- Debuting at ESC 2018, the EPIQ CVx places cardiologists at the forefront of innovation. It includes higher processing power, exceptional image clarity and sharpness, improved exam efficiencies and more robust and reproducible quantification, enabled by anatomical intelligence. The EPIQ CVx includes TrueVue, giving clinicians the ability to see photorealistic renderings of the heart, which improves cardiac anatomy analysis by offering detailed tissue and depth perception imaging through a new virtual light source. The system provides cardiologists with high image quality through the latest generation OLED monitor, offering a more dynamic, wider viewing angle for side-by-side image comparison. By combining the new OLED monitor with TrueVue, clinicians can have the confidence to provide exceptional care for all patients, including pediatric patients, whose small hearts can be challenging to image.
The system offers a variety of new features including Dynamic Heart Model. Building on Philips HeartModelA.., it uses anatomical intelligence to automatically quantify left ventricle function to produce a multi-beat analysis for adult patients. Dynamic Heart Model has been shown to reduce the amount of time to generate a 3D Ejection Fraction, an important measurement in determining how well the heart is pumping out blood, by 83% . It also delivers a high level of robustness and reproducibility, even for patients with an arrhythmia. The systems also includes the new S9-2 PureWave Transducer, which simplifies pediatric cardiac exams by displaying high levels of detail and contrast resolution through the single-crystal technology. It also provides tissue information at greater depths and enhances pediatric capability for coronary artery visualization.
The EPIQ CVx includes a cardiology-specific user interface that simplifies the exam experience through a user-configurable touch-screen interface, allowing clinicians to personalize their controls and improve workflow for their cardiology exams. Philips also reaffirms its dedication to privacy and security by providing strong security capabilities and protocols.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)